Stocks and Investing
Stocks and Investing
Fri, July 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Drew Ranieri Maintained (TMCI) at Buy with Decreased Target to $22 on, Jul 15th, 2022
Drew Ranieri of Morgan Stanley, Maintained "Treace Medical Concepts, Inc." (TMCI) at Buy with Decreased Target from $26 to $22 on, Jul 15th, 2022.
Drew has made no other calls on TMCI in the last 4 months.
There is 1 other peer that has a rating on TMCI. Out of the 1 peers that are also analyzing TMCI, 0 agree with Drew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Drew
- Ryan Zimmerman of "BTIG" Initiated at Strong Buy and Held Target at $22 on, Thursday, May 12th, 2022
Contributing Sources